#Netherlands #Amsterdam #Norgine #WHIM syndrome #XOLREMDI

Norgine's Landmark Approval in Europe for WHIM Syndrome Treatment

Norgine, a prominent specialty pharmaceutical company in Europe, has recently achieved a significant breakthrough in the healthcare sector by obtaining marketing authorisation from the European Commission (EC) for its drug XOLREMDI® (mavorixafor). This landmark decision marks the first approved treatment for WHIM syndrome within the European Union, providing hope to a community that has endured the challenges of this ultra-rare primary immunodeficiency without any sanctioned therapies until now.

What is WHIM Syndrome?

WHIM syndrome is a rare genetic disorder, characterized by four key symptoms: Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. The disorder is linked to a malfunction of the CXCR4 receptor, resulting in the impaired mobilization of white blood cells, leading to chronic infections and other serious health issues. Patients suffering from this condition have an elevated risk of recurrent and severe infections due to the low levels of neutrophils and lymphocytes in their blood.

The Critical Milestone

The EC's approval was granted under exceptional circumstances, reflecting the extremely rare nature of WHIM syndrome and the difficulties in providing comprehensive data on efficacy and safety, which often accompanies treatments for such uncommon diseases. The decision is based on positive outcomes from a pivotal Phase 3 clinical trial, a rigorous, multicenter, randomized study that involved participants aged 12 years and older diagnosed with WHIM syndrome.

Janneke van der Kamp, CEO of Norgine, stated, "This approval is a considerable advancement for individuals battling WHIM syndrome, a condition that previously had no approved treatment options. Our mission at Norgine is to deliver medicines that cater to unfulfilled medical needs across Europe, and we are eager to work alongside health authorities and professionals in the rare disease community to make mavorixafor accessible to those who qualify."

The Development Journey

Norgine's journey toward the approval of XOLREMDI® began with a partnership with X4 Pharmaceuticals, formalized through a licensing and supply agreement in January 2025. This collaboration is designed to streamline the commercialization of mavorixafor in Europe, Australia, and New Zealand, ensuring that the drug reaches patients that need it the most.

XOLREMDI® acts as a selective antagonist to the CXCR4 receptor, effectively preventing its interaction with CXCL12. With this mechanism, the drug aims to improve the circulation of mature neutrophils and lymphocytes, thereby reducing the risk of infections for patients with WHIM syndrome.

Implications for Patients and the Community

The health community has heralded this approval as transformative for patients and families living with WHIM syndrome. Echoing this sentiment, Johan Prevot, the Executive Director for IPOPI (the International Patient Organisation for Primary Immunodeficiencies) remarked, "This approval symbolizes a significant achievement for the WHIM syndrome community. The introduction of an authorized treatment is a critical step towards alleviating the burden faced by patients and families dealing with severe recurrent infections."

As the healthcare landscape evolves, the commitment of organizations like Norgine plays an essential role in ensuring that innovative treatments are not only developed but also made accessible to those in need. With an estimated 1,500 employees and a revenue of around $650 million annually, Norgine is determined to continue its mission of providing impactful medical solutions for various health concerns, from common ailments to rare diseases.

Conclusion

The approval of XOLREMDI® signifies a new era in the management of WHIM syndrome, embodying hope and progress for a rare patient population. All eyes are now on Norgine as it embarks on the path of commercializing this vital treatment, ultimately aiming to improve the quality of life for individuals living with this serious immunodeficiency. As the market prepares for this introduction, the collaborative efforts between pharmaceutical companies, health authorities, and patient advocacy groups will be crucial in making a meaningful impact on the lives of those affected.